BioNxt Solutions, Bayer, Morphosys - Using high-speed technology to beat cancer in men

BioNxt Solutions - Novel coating ensures rapid release of active ingredient

Anyone who has ever been unwell knows that moment when, after taking a medicine, the effect unfolds in the body, and the active ingredient does its work.

**This is where BioNxt comes in, with a novel coating technology for orally administered drugs and active ingredients. The faster the active ingredient of an orally administered drug unfolds its effect, the faster patients feel relief from their symptoms. A so-called coating technology is responsible for the commercial implementation. Particularly exciting for investors: this technology can be patented.

"With BioNxt already having established platforms for transdermal and oral soluble drug delivery, this acquisition of a novel coating technology for oral drugs is a significant step in expanding and consolidating our drug delivery expertise," said Hugh Rogers, CEO & Director of BioNxt.

The logic behind this is understandable: the faster a drug provides relief, the higher the repeat purchase or prescription. That is because the increased speed of symptom relief allows patients to return to their usual quality of life sooner.

BioNxt is dedicated to helping patients regain their quality of life. Its solutions at the point of care offer rapid diagnosis, associated rapid relief and gentle drug delivery. BioNxt sees itself as an accelerator, and its successes to date prove it right: the faster patients experience relief, the greater the appreciation of the successes BioNxt provides through its research and work.

Bayer - New results in the fight against prostate cancer

In recent decades, the number of new cases of prostate cancer within the group of adult men has increased worldwide. In Europe, approximately 2.6 million new cases are diagnosed each year.

Signs of prostate cancer include difficulty urinating, blood in the urine or seminal fluid, pain during ejaculation and in the back, pelvis or hips, and potency problems. These warning signs should be clarified immediately by a doctor so that a possible serious illness can be recognised and treated at an early stage.

Bayer is strongly committed to advancing oncology research and development, focusing on three scientific areas that have the potential to address the unmet needs of cancer patients.

These include:

1. next generation immuno-oncology
2. targeted radionuclide therapies
3. molecular precision oncology

Important data from all three areas will be presented at this year's conference to demonstrate Bayer's progress and achievements in oncology research. Precision oncology will be presented, underscoring Bayer's commitment to advancing the future of cancer treatment.

Bayer is committed to researching its prostate cancer drug, darolutamide, to help many men affected by the disease. Bayer remains committed to advancing the research and development of darolutamide and other innovative drugs to fight prostate cancer.

Morphosys - Achieves first results in the fight against bone marrow cancer

Myelofibrosis is a malignant and rare disease of the bone marrow that occurs in the form of primary myelofibrosis (PMF) or as a secondary consequence of another myeloproliferative disease. In Germany, about 0.5 to 1.5 out of 100,000 people develop this type of cancer every year. That corresponds to approximately 1,000 new cases per year, with the average age of those affected being around 65 years.

Men are affected slightly more often than women, accounting for 65% of cases. Although myelofibrosis is not inherited according to current knowledge, there are familial clusters. Morphosys AG completed enrolment in the study investigating its therapeutic in the fight against this insidious disease at the beginning of April. This is a Phase III study investigating the efficacy and safety of pelabresib, a BET inhibitor, in combination with ruxolitinib in patients with myelofibrosis who have not previously been treated with a JAK inhibitor.

Combination therapy is being studied in comparison to ruxolitinib alone. Top-line data will be published earlier than expected in late 2023, which is positive for the stock. Incyte (INCY) is currently in trials of its own BET inhibitor, which can be used in combination with Jakafi. The product is undergoing Phase I trials and being tested for efficacy. In addition, the Company has another product in Phase III, the PI3K inhibitor parsaclisib. This is being studied as a combination therapy with ruxolitinib in patients who do not respond adequately to ruxolitinib. Results are due to be published in 2023. However, class-wide safety overhang is a major problem, as has already been observed with Incyte. The Company had to withdraw the NDA for marginal zone lymphoma, follicular lymphoma and mantle cell lymphoma.

For patients who have already been diagnosed, speed is everything. That is where BioNxt Solutions comes in, with its novel coating technology that enables conventional agents to relieve disease symptoms more quickly. For pharma and doctors, this is one of the main arguments for helping sufferers. Anyone who has ever taken a drug in the hope that it would work quickly - and it didn't - appreciates the speed of drug release. On the other hand, more and more men should take a closer look at the shares of Bayer. The increase in prostate cancer seems concerning. It is all the more valuable that a company like Bayer is focusing on where a man's most precious asset is permanently at risk, and non-treatment could end fatally. Morphosys is also joining the fight against cancer, in this case, bone marrow cancer. Here, men are also more often affected than women. Investors should carefully consider who they are backing with their investment.